Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi TPredictive value of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 58: 161-164

Nagasaki University, Nagasaki, Nagasaki, Japan
Urology (Impact Factor: 2.19). 09/2001; 58(2):161-4. DOI: 10.1016/S0090-4295(01)01165-7
Source: PubMed


To determine the clinical significance and predictive value of three acute phase reactants (erythrocyte sedimentation rate, C-reactive protein, and ferritin), as well as basic fetoprotein (BFP) and immunosuppressive acidic protein, in patients with renal cell carcinoma.
Erythrocyte sedimentation rate, C-reactive protein, ferritin, BFP, and immunosuppressive acidic protein levels were measured in 92 patients with renal cell carcinoma diagnosed in 1989 to 1999. The levels were compared with the clinical stage and nuclear grade, and their predictive values of survival were evaluated statistically.
All markers, with the exception of BFP, correlated with each other and with the clinical stage and nuclear grade. BFP did not correlate with the acute phase reactants. The log-rank test revealed that the levels of C-reactive protein, immunosuppressive acidic protein, and ferritin significantly influenced survival. Multivariate stepwise analysis identified ferritin as the only independent and significant prognostic marker (hazard ratio = 5.624, P = 0.001). However, when age, sex, clinical stage, and nuclear grade were entered into the same analysis, only clinical stage was an independent marker of prognosis.
The results of our study demonstrated that serum ferritin is the most useful marker among five tested factors for staging and predicting survival, although the clinical stage is the best parameter that predicts the prognosis of patients with renal cell carcinoma accurately.

3 Reads
  • Source
    • "Third, cancer cells could increase the production of inflammatory cytokines, which could induce high CRP concentration in cancer patients.4 Many studies showed the elevation of pretreatment CRP to be a significant prognostic parameter in patients with esophageal cancer, 8-10 hepatocellular carcinoma,11 colorectal cancer,12-14 renal cell cancer,15-17 ovarian cancer,18 and non-small cell lung cancer (NSCLC).19-23 Furthermore, we recently reported an association between preoperative serum CRP levels and pathologic parameter such as tumor size and lymphovascular invasion in patients with NSCLC.24 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Elevated C-reactive protein (CRP) is associated with poor prognosis in several tumor types. The purpose of this study was to investigate serum CRP as a prognostic marker in small cell lung cancer (SCLC). The pretreatment serum CRP level was measured in 157 newly diagnosed SCLC patients, and correlation between serum CRP level and other clinical parameters was analyzed. Multivariate analyses were performed to find prognostic markers using Cox's proportional hazards model. The initial CRP concentration was within the normal range in 72 (45.9%) patients and elevated in 85 (54.1%) patients. There was a significant correlation between serum CRP level and the extent of disease (p<0.001), weight loss (p=0.029) and chest radiation (p=0.001). Median overall survival (OS) in the normal CRP group was significantly longer than with the high CRP group (22.5 months vs. 11.2 months, p<0.001). Extent of disease (p<0.001), age (p=0.025), and performance status (p<0.001) were additional prognostic factors on univariate analysis. On multivariate analysis, elevated serum CRP level was an independent prognostic factor for poor survival (HR=1.8; p=0.014), regardless of the extent of disease (HR=3.7; p<0.001) and performance status (HR=2.2; p<0.001). High level of CRP was an independent poor prognostic serum marker in addition to previously well-known prognosticators in patients with SCLC.
    Yonsei medical journal 01/2012; 53(1):111-7. DOI:10.3349/ymj.2012.53.1.111 · 1.29 Impact Factor
  • Source
    • "Cancer patients are known to exhibit a general state of chronic inflammation which, as stated above, is related to the tumor itself and the interaction of host factors with the tumor. Elevation in the level o f classical inflammatory markers such as fibrinogen [149-155], CRP [156-160], erythrocyte sedimentation rate [161], ferritin [162-165], neopterin [166-168], homocysteine [169,170], IL-6 [161,171], and free radical stress [172-175] have been well-documented in cancer patients, with numerous studies demonstrating that elevation is associated with poor survival. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis.
    Journal of Translational Medicine 03/2011; 9:25. DOI:10.1186/1479-5876-9-25 · 3.93 Impact Factor
  • Source
    • "However, in keeping with the findings of Ishimura et al. [20] and Gudbjartsson et al. [21], the independent prognostic significance of mode of presentation was not confirmed in multivariate analysis. In agreement with other studies, [4,22] we found that elevated ESR at presentation was associated with more aggressive disease and poorer outcome for both clear cell and papillary RCC (data not shown). Contrary to the study of Sengupta et al. [4] the frequency of elevated ESR among our patients was not significantly different between these two histological subtypes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate a possible prognostic significance of interactions between lymph node invasion (LNI), synchronous distant metastases (SDM), and venous invasion (VI) adjusted for mode of detection, Eastern Cooperative Oncology Group performance status (ECOG PS), erythrocyte sedimentation rate (ESR) and tumour size (TS) in 196 patients with renal cell carcinoma treated with radical nephrectomy. Median follow-up was 5.5 years (mean 6.9 years; range 0.01-19.4). The mode of detection, ECOG PS, ESR and TS were obtained from the patients' records. Vena cava invasion and distant metastases were detected by preoperative imaging. The surgical specimens were examined for pathological stage, LNI and VI. The univariate analyses showed significant impact of VI, LNI, SDM, ESR and TS (p < 0.001), as well as mode of detection (p = 0.003) and ECOG PS (p = 0.002) on cancer specific survival. In multivariate analyses LNI was significantly associated with survival only in patients without SDM or VI (p < 0.001) with a hazard ratio of 9.0. LNI lost its prognostic significance when SDM or VI was present. Our findings underline the prognostic importance of the status of the lymph nodes. LNI, SDM, ESR, and VI were independently associated with cancer specific survival after radical nephrectomy. LNI provided the strongest prognostic information for patients without SDM or VI whereas SDM and VI had strongest impact on survival when there was no nodal involvement.
    BMC Urology 12/2008; 8(1):19. DOI:10.1186/1471-2490-8-19 · 1.41 Impact Factor
Show more